Related Experiment Videos
[Arrhythmias in cardiomyopathies].
Yoshiaki Kaneko1, Masahiko Kurabayashi
1Second Department of Internal Medicine, Gunma University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 26, 2002
Summary
This review covers sudden cardiac death risk in dilated, hypertrophic, and arrhythmogenic cardiomyopathies. It highlights risk factors and treatments like amiodarone and implantable cardioverter-defibrillators for prevention.
Area of Science:
- Cardiology
- Electrophysiology
- Genetics
Context:
- Focuses on three primary cardiomyopathies: dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC).
- Addresses the critical issue of complicated arrhythmias and sudden cardiac death (SCD) within these conditions.
- Emphasizes the need for precise risk stratification to identify high-risk patient groups.
Purpose:
- To review the pathophysiology of arrhythmias and SCD in DCM, HCM, and ARVC.
- To discuss current risk stratification methods and therapeutic strategies for these cardiomyopathies.
- To inform clinical practice regarding the prevention of sudden cardiac death.
Summary:
- Pathophysiology of arrhythmias and SCD in DCM, HCM, and ARVC is detailed.
- Risk factors for SCD are identified for each cardiomyopathy type.
- Current treatment options, including amiodarone and implantable cardioverter-defibrillators (ICDs), are presented as preventive measures.
Impact:
- Aims to improve the identification and management of patients at risk for sudden cardiac death.
- Provides a consolidated overview of current knowledge for clinicians and researchers.
- Contributes to the reduction of mortality associated with cardiomyopathies through targeted therapeutic interventions.